Latest News

Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024

SHANGHAI, May 24, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced latest clinical research results on GC203 (a novel non-viral vector gene-modif...

2024-05-24 20:00 5449

Tyfon and Global Technology Acquisition Corp. I Announce Public Filing of Registration Statement on Form F-4 in Connection with Proposed Business Combination

•         Transaction expected to close in the second half of 2024 ZEPHYR COVE, Nev. and SUZHOU, China, May 24, 2024 /PRNewswire/ -- Global Technology Acquisition Corp. I (NASDAQ: GTAC) ("GTAC"), a special purpose acquisition company, and Tyfon Culture Holdings Limited ("Tyfon"), a well-recogniz...

2024-05-24 19:39 7751

XCMG Machinery Amplifies Presence in Latin America with More Tailor-Made Machines Launched

SAO PAULO, May 24, 2024 /PRNewswire/ -- In a significant move to strengthen its foothold in the Latin American market,XCMG Machinery ("XCMG", SHE:000425) has ramped up its operations, marking the 50th anniversary of the establishment of diplomatic relations betweenChina and Brazil. The company's ...

2024-05-24 19:27 5359

Rokid AR Lite: The first AR glasses powered by Snapdragon® 6 Gen 1 mobile platform

REDWOOD CITY, Calif., May 24, 2024 /PRNewswire/ -- Rokid  has announced the launch of its new AR device, the Rokid AR Lite, on Kickstarter, marking the first AR glasses powered by the Snapdragon® 6 Gen 1 Mobile Platform. This integration brings the power and versatilit...

2024-05-24 19:14 3228

Air Premia, Celebrates the First Anniversary of Its New York Route with Exceptional Performance

* In its first year of service, Air Premia's Incheon-New York route has quickly established itself as a preferred choice for travelers. To celebrate this milestone, Air Premia is offering a limited time special fares and additional flights. NEW YORK, May 24, 2024 /PRNewswire/ -- Hybrid airline ...

2024-05-24 19:00 4221

K-Pet develops disease prevention solutions to extend the healthy life of pets

SEOUL, South Korea, May 24, 2024 /PRNewswire/ -- On the 23rd, K-PET ( http://k-pet.fourdpocket.com/

2024-05-24 18:13 4537

CNFinance to Hold Annual General Meeting on June 7, 2024

GUANGZHOU, China, May 24, 2024 /PRNewswire/ -- CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced that it will hold its annual general meeting of shareholders (the "AGM") at 44/F, Tower G, No. 16 Zhujiang Do...

2024-05-24 18:00 5063

Atour Unveils Sustainability Records in 2023 With Milestone ESG Report

SHANGHAI, May 24, 2024 /PRNewswire/ -- May 23, Atour Lifestyle Holdings Limited (NASDAQ: ATAT), a leading hospitality and lifestyle company inChina, has released its inaugural Environmental, Social, and Governance (ESG) report for 2023. The report underscores the company's sustainability efforts...

2024-05-24 18:00 5347

36Kr Hosts "AI Partner • Advanced Productivity" Conference

BEIJING, May 24, 2024 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants inChina, today hosted its "AI Partner • Advanced Productivity" Conference inBeijing, exploring AI technology...

2024-05-24 18:00 6730

New Oriental Extends Share Repurchase Program

BEIJING, May 24, 2024 /PRNewswire/ -- New Oriental Education & Technology Group Inc. ("New Oriental" or the "Company") (NYSE: EDU and SEHK: 9901), a provider of private educational services inChina, today announced that its board of directors has authorized the Company to extend its share repurch...

2024-05-24 17:00 2819

Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor

SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid...

2024-05-24 16:33 2977

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA. * Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway. * The resistance to sunvozertinib could be thro...

2024-05-24 16:32 3032

Newrizon Partnered With Al Yemni Group, Bringing Its Futuristic EV Truck In GCC Region

RIYADH, Saudi Arabia , May 24, 2024 /PRNewswire/ -- Recently in Riyadh, Newrizon , a startup dedicated in electrifying and revolutionizing urban delivery vehicles,signed dealership agreement and intent purchase order with Al Yemni Group, authorizing it as Newrizon's exclusive dealer in the GCC reg...

2024-05-24 16:03 3311

HoneyNaps secures a $11.6 million Series B investment, becoming the No. 1 ranked A.I Sleep Technology Company

HoneyNaps secures $11.6 million in series B funding, propelling its entry into the American medical market. BOSTON, May 24, 2024 /PRNewswire/ -- HoneyNaps, an industry-leading South Korean company in artificial intelligence (AI) sleep data analysis, announced on the 7th that it has closed its se...

2024-05-24 13:00 2715

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations a...

2024-05-24 09:15 3346

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 23, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharm...

2024-05-24 08:00 3206

Infobird Co., Ltd Receives Notification from Nasdaq for Failure to Timely File Form 20-F

HONG KONG, May 23, 2024 /PRNewswire/ -- Infobird Co., Ltd (NASDAQ: IFBD) ("Infobird" or the "Company"), a software-as-a-service provider of AI-powered customer engagement solutions inChina, today reports that as of May 16, 2024, it is delinquent in filing its annual report on Form 20-F for the fi...

2024-05-24 06:00 4802

SEMIFIVE Signs MOU with Atron Technologies to Collaborate on Semiconductor Design

Expected to expand global business in the Chinese market SEOUL, South Korea, May 23, 2024 /PRNewswire/ -- SEMIFIVE, a leading design solution provider and pioneer of platform-based custom silicon solutions, has announced its agreement of MOU withChina-based Atron Technologies, on May 23, 2024. T...

2024-05-24 06:00 4728

Emeren Announces First Quarter 2024 Financial Results

STAMFORD, Conn., May 23, 2024 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com ) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced its unaudited financial results for the first quarter endedMarch 31, 202...

2024-05-24 04:05 4663

Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024

SUZHOU, China, May 23, 2024 /PRNewswire/ -- On May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell carcinoma (R/R mRCC) in an oral presentation at the 27th Annual Meeting of the Americ...

2024-05-23 23:00 3594